三生制药与辉瑞达成60亿美元交易:双抗药物市场重构,中国药企全球化突围

21世纪经济报道
20 May

21世纪经济报道记者季媛媛上海报道国产双抗药物License-out(对外授权)再迎新进展。5月20日,三生国健(688336.SH)宣布,公司及关联方三生制药和沈阳三生制药有限责任公司(以下简称“沈阳三生”)共同授予辉瑞PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的独家开发、生产、商业化权利。辉瑞保留通过支付额外付款获得在中国大陆商业化许可产品的权利。根据协议,辉瑞将...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10